NASDAQ:LGND Ligand Pharmaceuticals (LGND) Stock Price, News & Analysis $108.99 -1.12 (-1.02%) (As of 07/31/2024 ET) Add Compare Share Share Today's Range$106.42▼$112.1350-Day Range$77.82▼$110.1152-Week Range$49.24▼$112.13Volume138,116 shsAverage Volume149,674 shsMarket Capitalization$1.96 billionP/E Ratio21.08Dividend YieldN/APrice Target$127.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Ligand Pharmaceuticals alerts: Email Address Ligand Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside16.8% Upside$127.25 Price TargetShort InterestBearish6.11% of Shares Sold ShortDividend StrengthN/ASustainability-1.57Upright™ Environmental ScoreNews Sentiment0.38Based on 9 Articles This WeekInsider TradingSelling Shares$2.15 M Sold Last QuarterProj. Earnings Growth29.94%From $3.54 to $4.60 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.35 out of 5 starsMedical Sector147th out of 928 stocksPharmaceutical Preparations Industry64th out of 434 stocks 2.5 Analyst's Opinion Consensus RatingLigand Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageLigand Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.Read more about Ligand Pharmaceuticals' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.11% of the outstanding shares of Ligand Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverLigand Pharmaceuticals has a short interest ratio ("days to cover") of 7.9.Change versus previous monthShort interest in Ligand Pharmaceuticals has recently increased by 17.72%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldLigand Pharmaceuticals does not currently pay a dividend.Dividend GrowthLigand Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreLigand Pharmaceuticals has received a 67.85% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Antihypertensives (C02)", "Pneumococcal vaccines", "Quinolones", "Fosphenytoin", "Antifungal medication (D01) ", and "Bevacizumab" products. See details.Environmental SustainabilityThe Environmental Impact score for Ligand Pharmaceuticals is -1.57. Previous Next 2.4 News and Social Media Coverage News SentimentLigand Pharmaceuticals has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Ligand Pharmaceuticals this week, compared to 4 articles on an average week.Search Interest1 people have searched for LGND on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Ligand Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ligand Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,150,882.00 in company stock.Percentage Held by InsidersOnly 5.90% of the stock of Ligand Pharmaceuticals is held by insiders.Percentage Held by Institutions91.28% of the stock of Ligand Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Ligand Pharmaceuticals' insider trading history. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Ligand Pharmaceuticals are expected to grow by 29.94% in the coming year, from $3.54 to $4.60 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ligand Pharmaceuticals is 21.08, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 141.47.Price to Earnings Ratio vs. SectorThe P/E ratio of Ligand Pharmaceuticals is 21.08, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 143.11.Price to Book Value per Share RatioLigand Pharmaceuticals has a P/B Ratio of 2.70. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Ligand Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyNvidia insiders dumping sharesAll the signs show the AI market is about to reverse. And unless you know what’s really going on in this sector, you could be wiped out. Inside this new expose, you'll discover exactly how the AI crisis will unfold... how you can prepare for it before it's too late... and how you can potentially profit from it, too. Click here to read the new expose, The Big AI Die-Up while you still can.To see Porter Stansberry's new AI prediction go here now. About Ligand Pharmaceuticals Stock (NASDAQ:LGND)Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.Read More LGND Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LGND Stock News HeadlinesJuly 10, 2024 | marketbeat.com5 Best Short-Term Stocks to Consider Investing InNot every investor is in the market for the long haul. Some prefer short time frames and volatile stocks, looking to make a profit in days or weeks rather than years.July 30 at 1:13 PM | benzinga.comAssessing Ligand Pharmaceuticals: Insights From 6 Financial AnalystsJuly 31, 2024 | Behind the Markets (Ad)J.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."July 25, 2024 | ca.finance.yahoo.comLGND Aug 2024 65.000 putJuly 24, 2024 | ca.finance.yahoo.comLGND Aug 2024 50.000 putJuly 8, 2024 | businesswire.comLigand to Acquire APEIRON Biologics AG for $100 MillionJune 27, 2024 | businesswire.comLigand Partner Verona Pharma Announces FDA Approval of Ohtuvayre™ (ensifentrine), First Inhaled Novel Mechanism for Maintenance Treatment of COPD in More Than 20 YearsJune 18, 2024 | businesswire.comLigand Collaborator Merck Receives FDA Approval for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for AdultsJuly 31, 2024 | Behind the Markets (Ad)J.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."May 25, 2024 | morningstar.comLigand Pharmaceuticals Inc LGNDMay 23, 2024 | businesswire.comLigand to Participate in Upcoming Investor ConferencesMay 20, 2024 | investorplace.com3 Must-Buy Biotech Stocks Before the Summer Rally Kicks OffMay 17, 2024 | investing.comLigand Pharmaceuticals director Nancy Gray sells shares worth over $77kMay 17, 2024 | investing.comLigand Pharmaceuticals CFO sells over $1.1 million in stockMay 16, 2024 | finance.yahoo.comInsider Sale: President & Chief Operating Officer Matthew Korenberg Sells Shares of Ligand ...May 14, 2024 | markets.businessinsider.comLigand Moves to Strong Buy: Rationale Behind the UpgradeMay 9, 2024 | finance.yahoo.comLigand Pharmaceuticals First Quarter 2024 Earnings: EPS: US$4.86 (vs US$2.56 in 1Q 2023)May 8, 2024 | finance.yahoo.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2024 Earnings Call TranscriptSee More Headlines Receive LGND Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ligand Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today7/31/2024Next Earnings (Confirmed)8/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:LGND CUSIP53220K50 CIK886163 Webwww.ligand.com Phone(858) 550-7500Fax858-550-1826Employees58Year FoundedN/APrice Target and Rating Average Stock Price Target$127.25 High Stock Price Target$144.00 Low Stock Price Target$95.00 Potential Upside/Downside+19.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)$5.17 Trailing P/E Ratio20.58 Forward P/E Ratio30.06 P/E GrowthN/ANet Income$52.15 million Net Margins79.30% Pretax Margin102.75% Return on Equity8.52% Return on Assets7.50% Debt Debt-to-Equity RatioN/A Current Ratio20.70 Quick Ratio19.51 Sales & Book Value Annual Sales$131.31 million Price / Sales14.59 Cash Flow$4.90 per share Price / Cash Flow21.74 Book Value$40.39 per share Price / Book2.63Miscellaneous Outstanding Shares18,000,000Free Float16,938,000Market Cap$1.92 billion OptionableOptionable Beta1.01 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Matthew E. Korenberg (Age 49)President & COO Comp: $831.77kMr. Octavio Espinoza (Age 53)Chief Financial Officer Comp: $613.59kMr. Andrew T. Reardon J.D. (Age 49)Chief Legal Officer & Secretary Comp: $614.87kMr. Scott M. Plesha (Age 59)Chief Executive Officer Mr. Paul J. HaddenSenior Vice President of Investments & Business DevelopmentSimon LatimerHead of Investor RelationsMr. Todd PettingillDirector of Corporate DevelopmentMs. Audrey Warfield-GrahamChief People OfficerDr. Keith MarschkeSenior Vice President of Biology & Scientific AffairsDr. Vincent D. Antle (Age 55)Senior Vice President of Technical Operations & QA - Capitsol More ExecutivesKey CompetitorsNurix TherapeuticsNASDAQ:NRIXPraxis Precision MedicinesNASDAQ:PRAXTravere TherapeuticsNASDAQ:TVTXArcturus TherapeuticsNASDAQ:ARCTCOMPASS PathwaysNASDAQ:CMPSView All CompetitorsInsiders & InstitutionsRothschild Investment LLCBought 406 shares on 7/31/2024Ownership: 0.002%Kings Path Partners LLCBought 6,880 shares on 7/30/2024Ownership: 0.038%F M Investments LLCBought 134,710 shares on 7/29/2024Ownership: 0.748%Principal Financial Group Inc.Sold 3,355 shares on 7/29/2024Ownership: 0.493%Innealta Capital LLCBought 367 shares on 7/29/2024Ownership: 0.002%View All Insider TransactionsView All Institutional Transactions LGND Stock Analysis - Frequently Asked Questions How have LGND shares performed this year? Ligand Pharmaceuticals' stock was trading at $71.42 on January 1st, 2024. Since then, LGND shares have increased by 52.6% and is now trading at $108.99. View the best growth stocks for 2024 here. How were Ligand Pharmaceuticals' earnings last quarter? Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) issued its quarterly earnings data on Tuesday, May, 7th. The biotechnology company reported $3.84 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.83 by $3.01. The business's revenue for the quarter was down 29.8% on a year-over-year basis. What is John L. Higgins' approval rating as Ligand Pharmaceuticals' CEO? 1 employees have rated Ligand Pharmaceuticals Chief Executive Officer John L. Higgins on Glassdoor.com. John L. Higgins has an approval rating of 100% among the company's employees. This puts John L. Higgins in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. Who are Ligand Pharmaceuticals' major shareholders? Top institutional investors of Ligand Pharmaceuticals include Bank of New York Mellon Corp (0.81%), F M Investments LLC (0.75%), Allspring Global Investments Holdings LLC (0.55%) and Principal Financial Group Inc. (0.49%). Insiders that own company stock include John L Higgins, Matthew W Foehr, Matthew E Korenberg, Todd C Davis, John W Kozarich, Stephen L Sabba, Octavio Espinoza, Andrew Reardon and Nancy Ryan Gray. View institutional ownership trends. How do I buy shares of Ligand Pharmaceuticals? Shares of LGND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Ligand Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ligand Pharmaceuticals investors own include Jazz Pharmaceuticals (JAZZ), Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), AbbVie (ABBV) and Netflix (NFLX). This page (NASDAQ:LGND) was last updated on 7/31/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredObama wins Presidential debate When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ligand Pharmaceuticals Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Ligand Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LGND Stock Alerts